UNSPSC 51202001: Temsirolimus

This classification denotes a mtor inhibitor with the molecular formula C56H87NO16, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 624KN6GM2T, chemically known as rapamycin, 42-(3-hydroxy-2-(hydroxymethyl)-2-methylpropanoate) but generally known as temsirolimus, which bears US NIH Compound Identifier 6440033. European Medicines Agency schedules Temsirolimus in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB21308.

UNSPSC 51202001 Temsirolimus is a Commodity code that covers pharmaceutical products used in oncology and immunosuppressive therapy. However, the recent state and local solicitation activity tagged under this code reflects a significant mismatch: the Mississippi State Department of Health posted a sole source procurement notice for Yellow Fever Vaccine from Sanofi Pasteur, Inc., which falls outside the scope of temsirolimus and represents a different pharmaceutical category entirely. State and local procurement under this code appears limited in volume, with the recent opportunity being a vaccine procurement rather than the specialty pharmaceutical or cancer-treatment drug that the code nominally encompasses. Issuing bodies for pharmaceutical procurements of this type typically include state health departments and Medicaid agencies, which manage drug formularies and negotiate contracts for hospital systems, clinics, and treatment facilities within their jurisdictions.

The recent activity concentrates in the Southeast, with the Mississippi State Department of Health's sole source notice posted July 13, 2026, with an objection deadline of August 3, 2026 at 10:00 a.m. CST. The solicitation is not a standard competitive RFP or IFB but rather a notice of proposed sole source purchase, allowing interested vendors to challenge the single-source designation if they can demonstrate alternative supply availability. The notice does not disclose quantity, contract term, or estimated value. The mismatch between the code's nominal scope (temsirolimus) and the actual recent opportunity (yellow fever vaccine) suggests this code may see limited relevant activity in state and local procurement right now, or that state purchasing offices are applying the code inconsistently.